Filling the need for trusted information on national health issues

Financial Times Examines Implications Of Controversy Over Indian HPV Vaccination Study

The Financial Times examines how the deaths of seven female participants of a study on the cost and feasibility of incorporating human papillomavirus (HPV) vaccines “into India’s public sector immunization program” has affected opinions of drug trials in the country. “[T]he program to vaccinate 14,000 adolescent girls from poor families ran into trouble after seven died soon after their vaccinations,” the newspaper notes. Though “[t]he causes of the girls’ deaths were never established or conclusively linked to the HPV vaccine … serious questions were raised over whether the participants’ parents — many of whom were illiterate — had given informed consent, and whether the project adequately tracked any adverse reactions,” the newspaper writes, adding, “The ensuing media and political storm — highlighting sensitivities around drug trials in the developing world — has contributed to the restrictions on such studies, affecting both Indian and global pharmaceutical companies” (Kazmin, 11/18).